Halozyme Therapeutics (NASDAQ:HALO) CFO Sells $1,514,200.00 in Stock

Key Points

• Halozyme Therapeutics CFO Nicole Labrosse sold 20,000 shares of the company's stock for approximately $1.51 million, marking a 45.14% decrease in her ownership position.
• The company reported $1.54 EPS in its latest quarterly earnings, surpassing estimates and achieving 40.8% year-over-year revenue growth.
• Several hedge funds have increased their stakes in Halozyme, with institutional investors holding 97.79% of the company's stock.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CFO Nicole Labrosse sold 20,000 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares of the company's stock, valued at $1,840,207.26. This trade represents a 45.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded up $1.73 during trading on Thursday, reaching $77.53. 2,218,356 shares of the company's stock were exchanged, compared to its average volume of 1,967,735. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $77.58. The company has a market cap of $9.07 billion, a P/E ratio of 17.74, a PEG ratio of 0.42 and a beta of 1.19. The firm's 50-day moving average price is $64.18 and its 200 day moving average price is $60.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. During the same quarter in the previous year, the firm earned $0.91 EPS. Halozyme Therapeutics's revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its stake in shares of Halozyme Therapeutics by 80.9% in the second quarter. Osaic Holdings Inc. now owns 53,448 shares of the biopharmaceutical company's stock valued at $2,972,000 after buying an additional 23,910 shares during the period. Cim Investment Management Inc. boosted its position in shares of Halozyme Therapeutics by 100.7% during the 2nd quarter. Cim Investment Management Inc. now owns 17,924 shares of the biopharmaceutical company's stock valued at $894,000 after purchasing an additional 8,995 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $32,000. Advisory Services Network LLC bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $606,000. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $871,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on HALO. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. HC Wainwright upped their target price on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. Zacks Research raised Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 2nd. Finally, JMP Securities upped their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $67.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.